Мы используем файлы cookie.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Uridine triacetate
Другие языки:

    Uridine triacetate

    Подписчиков: 0, рейтинг: 0

    Uridine triacetate
    Uridine triacetate structure.svg
    Clinical data
    Trade names Vistogard, Xuriden
    Other names vistonuridine
    AHFS/Drugs.com Monograph
    MedlinePlus a616020
    License data
    Routes of
    administration
    By mouth
    ATC code
    Legal status
    Legal status
    Pharmacokinetic data
    Metabolism Pyrimidine catabolic pathway
    Onset of action Tmax = 2–3 hours
    Elimination half-life 2–2.5 hours
    Excretion Kidney
    Identifiers
    • [(2R,3R,4R,5R)-3,4-diacetyloxy-5-(2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methyl acetate
    CAS Number
    PubChem CID
    DrugBank
    ChemSpider
    UNII
    KEGG
    ChEBI
    ChEMBL
    CompTox Dashboard (EPA)
    ECHA InfoCard 100.021.710
    Chemical and physical data
    Formula C15H18N2O9
    Molar mass 370.314 g·mol−1
    3D model (JSmol)
    • CC(=O)OCC1C(C(C(O1)N2C=CC(=O)NC2=O)OC(=O)C)OC(=O)C
    • InChI=1S/C15H18N2O9/c1-7(18)23-6-10-12(24-8(2)19)13(25-9(3)20)14(26-10)17-5-4-11(21)16-15(17)22/h4-5,10,12-14H,6H2,1-3H3,(H,16,21,22)/t10-,12-,13-,14-/m1/s1
    • Key:AUFUWRKPQLGTGF-FMKGYKFTSA-N

    Uridine triacetate (INN), formerly known as vistonuridine, is an orally active tri-acetylated prodrug of uridine used:

    • in the treatment of hereditary orotic aciduria (brand name Xuriden /ˈzʊərədɛn/ ZOOR-ə-den);
    • to treat people following an overdose of chemotherapy drugs 5-fluorouracil (5-FU) or capecitabine regardless of the presence of symptoms, or who exhibit early-onset, severe or life-threatening toxicity affecting the cardiac or central nervous system, and/or early-onset, unusually severe adverse reactions (e.g., gastrointestinal toxicity and/or neutropenia) within 96 hours following the end of fluorouracil or capecitabine administration (brand name Vistogard).

    Uridine triacetate was developed, manufactured and distributed by Wellstat Therapeutics. It was granted breakthrough therapy designation by the U.S. Food and Drug Administration (FDA) and approved for use in the United States in 2015.

    External links



    Новое сообщение